Journal of Medicinal Chemistry Article

J. Med. Chem. **2010,** *53,* 6477–6489 **6477**
DOI: 10.1021/jm1006484

Synthesis, Structure−Activity Relationship, and Mode-of-Action Studies of Antimalarial Reversed Chloroquine Compounds

Steven J. Burgess,[†,‡] Jane X. Kelly,[†,§] Shawheen Shomloo,[†,‡] Sergio Wittlin,[∥,⊥] Reto Brun,[∥,⊥] Katherine Liebmann,[†] and David H. Peyton*[,†,‡]

[†]*Department of Chemistry, Portland State University, P.O. Box 751, Portland, Oregon 97207-0751,* [‡]*DesignMedix, Inc., 2828 SW Corbett Avenue, Portland, Oregon 97201,* [§]*Portland Veterans Affairs Medical Center, Portland, Oregon 97239,* [∥]*Swiss Tropical and Public Health Institute, Basel, Switzerland, and* [⊥]*University of Basel, Basel, Switzerland*

Received May 28, 2010

We have previously shown that a "reversed chloroquine (RCQ)" molecule, composed of a chloroquine-like moiety and a resistance reversal-like moiety, can overcome chloroquine resistance in *P. falciparum* (Burgess, S. J.; Selzer, A.; Kelly, J. X.; Smilkstein, M. J.; Riscoe, M. K.; Peyton, D. H. *J. Med. Chem.* **2006**, *49*, 5623. Andrews, S.; Burgess, S. J.; Skaalrud, D.; Kelly, J. X.; Peyton, D. H. *J. Med. Chem.* **2010**, *53*, 916). Here, we present an investigation into the structure−activity relationship of the RCQ structures, resulting in an orally active molecule with good in vitro and in vivo antimalarial activity. We also present evidence of the mode of action, indicating that the RCQ molecules inhibit hemozoin formation in the parasite's digestive vacuole in a manner similar to that of chloroquine.

Introduction

Malaria remains among the most important diseases, with nearly half of the world's population at risk of infection and ~250 million cases reported annually.[1] Malaria kills nearly a million people each year, 90% of whom are African children. Of the different *Plasmodium* parasites known to give human malaria infections, *P. falciparum* is the most deadly, although the others still result in serious illness that can turn fatal. There are a number of drugs available to treat malaria, yet *P. falciparum* has developed resistance to almost all of them. Even the artemisinin class of drugs is now showing worrying signs of reduced efficacy,[1−6] and so there is a continuing need for a pipeline of new antimalarial treatments to combat the disease.

Chloroquine (CQ[a]) was first introduced in the 1940s and quickly became the drug of choice for the treatment of malaria. CQ has several advantages over other antimalarial drugs: its low cost made it available to everyone; its low toxicity meant it was safe for children and pregnant women, the most vulnerable victims of malaria; its good efficacy meant the treatment regime was simple and easy to administer. However, resistance developed within about a decade and spread to such an extent that today the World Health Organization (WHO) recommends CQ not be used for the treatment of *P. falciparum* malaria except in specific areas.[1]

CQ resistance in *P. falciparum* is strongly linked to mutations in the gene *pfcrt* that gives rise to the protein, PfCRT (*P. falciparum* chloroquine resistance transporter), located in the parasite's digestive vacuole (DV) membrane.[7−10] In chloroquine resistant (CQR) *P. falciparum* there is reduced accumulation of CQ in the DV due to increased efflux.[9,11] PfCRT is a putative member of the drug/metabolite transporter superfamily, and recent evidence suggests that the mutated forms are in fact the transporters directly responsible for exporting CQ from the DV of *P. falciparum*.[12]

There are molecules such as verapamil and desipramine that have been found to reverse the effects of CQ resistance.[11,13,14] These are known as reversal agents (RAs) or chemosensitizers. Many of these compounds are existing drugs, such as antidepressants or antihistamines, and at the high doses often required to achieve optimal reversal activity there can be problems with unpleasant side effects.[15] A pharmacophore consisting of two aromatic rings and an aliphatic nitrogen a few angstroms away has been derived from a set of such RAs.[16]

Our previous work demonstrated that the hybrid molecule **1** can be synthesized, containing elements from both CQ and the RA pharmacophore (Figure 1).[17] This prototype "reversed chloroquine" (RCQ) molecule gave IC_{50} values lower than CQ for both CQR and chloroquine sensitive (CQS) *P. falciparum* strains and demonstrated oral efficacy against *P. chabaudi* in mice. A subsequent structure−activity relationship (SAR) study demonstrated that the linkage between the 7-chloro-4-aminoquinoline moiety from CQ and the aromatic rings of the RA headgroup could be varied in length without serious loss of activity and that the RA portion itself could be substantially varied without serious loss of activity against CQR or CQS *P. falciparum* malaria strains.[18] The work presented here is the result of a more extensive SAR study, with further variations to both the linkage and the aromatic headgroup of the RA moiety. The result is an orally efficacious molecule with good in vitro and in vivo antimalarial activity.

*To whom correspondence should be addressed. Phone: 503-725-3875. Fax: 503-725-9525. E-mail: peytond@pdx.edu.

[a] Abbreviations: CQ, chloroquine; WHO, World Health Organization; PfCRT, *Plasmodium falciparum* chloroquine resistance transporter; DV, digestive vacuole; CQR, chloroquine resistant; CQS, chloroquine sensitive; RA, reversal agent; RCQ, reversed chloroquine compound; SAR, structure−activity relationship; RBC, red blood cell; PRBC, parasitized red blood cell.

Published on Web 08/04/2010

Chemistry

The synthesis of **3b** has been previously described,[17] and **3a** was similarly synthesized (Scheme 1). These were treated with 1-(diphenylmethyl)piperazine or **27**−**29** (Scheme 2) to give the RCQ compounds **4**−**12**. RCQ compound **13**, the two-carbon linker analogue of **1**, was synthesized by treating **3a** with desipramine hydrochloride. The intermediate compound **14** was made by first treating **2b** with methanesulfonyl chloride, then adding an excess of piperazine (Scheme 1). This was subsequently treated with trityl chloride to give **15**. **16** and **17** were synthesized from diphenylacetaldehyde and 2-adamantanone, respectively, by reductive amination onto **14**.[19] The dipyridyl analogues were synthesized by first treating 4-aminopiperidine with 2,2′-dipyridyl ketone to give **18** (Scheme 3).



Figure 1. Prototype reversed chloroquine molecule **1**. The dashed boxes show the chloroquine and reversal agent (imipramine) portions of the molecule.

Scheme 2. Synthesis of RA Headgroups **27**−**29**[a]



[a] Reagents and conditions: R-Br or R-Cl, homopiperazine, chloroform, reflux.

Scheme 1. Synthesis of the Intermediate Molecules **2a**,**b**, **3a**,**b**, and **14** and the Reversed Chloroquine Molecules **4**−**13** and **15**−**17**[a]



[a] Reagents and conditions: (i) 2-aminoethanol or 3-aminopropanol, 140 °C; (ii) methanesulfonyl chloride, Et_3N, dichloromethane, 5 °C; (iii) appropriate piperazine or homopiperazine compound, Et_3N, **3a** or **3b**, THF, 70 °C; (iv) (1) desipramine HCl, $NaHCO_3$, dichloromethane; (2) **3a**, Et_3N, THF, 60 °C; (v) **2b**, Et_3N, methanesulfonyl chloride, THF, 0 °C, piperazine, reflux; (vi) trityl chloride, K_2CO_3, acetonitrile, reflux; (vii) diphenylacetaldehyde, $Na(AcO)_3BH$, acetic acid, THF, room temperature; (viii) 2-adamantanone, $Na(AcO)_3BH$, acetic acid, THF, room temperature.

Scheme 3. Synthesis of the Dipyridyl Compounds **21** and **22**[a]



[a] Reagents and conditions: (i) 2,2′-dipyridylketone, pTSA, toluene, reflux; (ii) **3a** or **3b**, K_2CO_3, acetonitrile, 70 °C; (iii) $NABH_4$, methanol, room temperature.

Scheme 4. Synthesis of the Four-Carbon Analogue **25**[a]



[a] Reagents and conditions: bromobutylphthalimide, K_2CO_3, acetonitrile, reflux; (ii) hydrazine hydrate, ethanol, reflux; (iii) 4,7-dichloroquinoline, Et_3N, ethanol, reflux.

Scheme 5. Synthesis of **26**, the RA Headgroup without a Quinoline Ring Attached[a]



[a] Reagents and conditions: K_2CO_3, KI, DMF, 70 °C.

This was then treated with methane sulfonate esters **3a** and **3b** to give **19** and **20**, respectively, which were reduced in the presence of sodium borohydride to give **21** and **22**. Initial attempts to make **25**, the four-carbon linker analogue of **4** and **5**, by an analogous route failed because of intramolecular cyclization of the activated alcohol to form a pyrrolidine ring at the 4-position of the quinoline. Therefore, a different route was employed (Scheme 4). 1-(Diphenylmethyl)piperazine was treated with *N*-(4-bromobutyl)phthalamide to give **23**, then deprotected with hydrazine to give **24**. This was treated with 4,7-dichloroquinoline to give **25**. To make the unattached RA headgroup **26**, chlorodiphenylmethane was treated with 1-(2-hydroxyethyl)piperazine in the presence of potassium carbonate (Scheme 5).

Results and Discussion

After the success of the prototype molecule **1** in overcoming CQ resistance, compounds **4** and **5** were designed to modify the structure of the RA headgroup slightly, moving away from the initial, tricyclic antidepressant, imipramine structure. In keeping with the published pharmacophore,[16] the 1-(diphenylmethyl)piperazine retained the two aromatic rings and the protonatable nitrogen. However, the connector was now a piperazinyl ring which, it was hoped, would make the compounds more stable to metabolic cleavage. A secondary advantage was that it was easy to design a SAR study around this structure from inexpensive and readily available starting materials. Thus compounds **6**−**12** and **15**−**17** were also synthesized, varying the length of the chain from the quinoline to the piperazine ring, changing the piperazine to a homopiperazine, or varying the RA aromatic headgroup. Compound **13** gave the two-carbon linker analogue of **1**. As can be seen in Table 1, the in vitro results from these first compounds against *P. falciparum* malaria strains were favorable. While some did not quite match CQ against CQS D6, they all were more active than CQ against the two tested CQR strains.

The general cytotoxic effect was assessed by functional assay using mitogen-stimulated murine spleenic lymphocytes. The therapeutic indices for the RCQ compounds were calculated as the ratio of cytotoxicity IC_{50} to antimalarial IC_{50} against Dd2 (Table 1).

Although the in vitro data for **1**, **4**, **5**−**13**, and **15**−**17** were promising, all of these compounds suffer from high ClogP values. This suggested that they could have limited water solubility, and so oral availability might be impaired, although formulating as salts and/or cocrystals or other strategies may mitigate this concern. A modification to the aromatic headgroup was designed using pyridines in place of the phenyl groups. Compounds **21** and **22** had ClogP values of 3.3 and 3.6, respectively, and IC_{50} values comparable to the best of the previous compounds (Table 1). For comparison, CQ has a ClogP value of 5.1. The therapeutic index values for these compounds are substantially greater than 10-fold above that of CQ. The result of the SAR is a collection of compounds

Table 1. IC_{50} of RCQ Compounds against Three *P. falciparum* Strains CQS D6, CQR Dd2, and 7G8, ClogP, Cytotoxicity Data against Mouse Spleen Lymphocytes, and a Therapeutic Index Calculated from the Cytotoxicity and Dd2 IC_{50}

	IC_{50} (nM) for *P. falciparum*[a]					
compd	D6	Dd2	7G8	cytotoxicity (nM)[b]	therapeutic index (Dd2 strain)[c]	ClogP[d]
CQ	6.9	102	106	12000	122	5.1
1	2.9	5.3	4.0	700	132	8.8
4	1.0	3.6	4.3	1900	528	7.2
5	1.9	2.6	11	1100	423	7.4
6	4.8	4.1	15	700	171	7.4
7	2.6	2.0	10	1400	700	7.8
8	3.2	3.5	12	800	229	8.0
9	6.6	5.7	22	900	158	8.0
10	2.0	2.4	34	4100	1710	7.6
11	9.2	9.6	41	2500	260	7.0
12	21	15	56	2500	167	7.3
13	3.6	5.2	21	1400	269	8.5
14	4.3	6.8	nt[e]	23000	3380	3.4
15	2.0	4.2	10	57000	13600	8.9
16	0.5	3.3	3.4	23000	6970	6.4
17	0.8	1.8	10	130000	69400	6.5
21	1.1	3.9	7.4	29000	7310	3.3
22	0.9	1.6	1.8	6500	4060	3.6
25	1.3	1.3	7.2	1100	846	7.5
26	> 2500	> 2500	> 2500	130000	> 50	3.2

[a] Averages of at least three runs (±15%). The uncertainties are estimated based on weighing uncertainties for the various compounds (free bases and often oils) and on variability between determinations that were performed in different weeks. In order to compare results run on different days and with different batches of each stain, CQ was run as a positive control. All results obtained were "normalized" to the CQ values of 6.9 nM for D6, 102 nM for Dd2, and 108 nM for 7G8. For example, the normalized IC_{50} for an RCQ compound tested against a D6 strain is $[6.9/IC_{50}(CQ\ (D6))] \times IC_{50}$(RCQ compound (D6)). [b] Cytotoxicity is tested against mouse spleen lymphocytes. [c] Therapeutic index for the Dd2 strain is given by the ratio of the cyctoxicity divided by the IC_{50} for Dd2. [d] ClogP values calculated for the un-ionized forms of the compounds, using ChemDrawUltra 11.0. [e] nt: not tested.

with high potencies against CQS and CQR malaria strains, low cytotoxicities, and with ClogP values bracketing that of CQ.

It has previously been shown that simply changing the chain length of CQ can circumvent the PfCRT-associated CQR mechanism.[20−22] All of the RCQ molecules thus far synthesized had either a two- or three-carbon chain between the tertiary nitrogen and the aminoquinoline, so **25**, which has the same length linker between the quinoline ring and the aliphatic nitrogen as CQ, was made and evaluated by the in vitro methods applied above. As can be seen in Table 1, the activity of **25** against both CQS and CQR *P. falciparum* is better than that of CQ and comparable to both **4** and **5**, the two- and three-carbon analogues. These results, combined with other work from our group,[18] demonstrate that the ability to overcome CQR by the addition of a RA headgroup to the 4-aminoquinoline ring is, in fact, independent of the chain length between them, at least if the chain length is between two and four carbons.

In Vivo Efficacy against *Plasmodium berghei*. **1**, **4**, **15**, and **22** were tested in vivo in a *P. berghei* rodent model. Three sets of conditions were used: 1 dose of 30 mg/kg administered orally, 1 dose of 30 mg/kg administered subcutaneously, and 4 × 30 mg/kg dose delivered orally. The subcutaneous series provided a convenient alternative to the oral route, in case absorption across the intestine was problematic. The percent activity was calculated as the difference between the mean percent parasitemia for the control and treated groups expressed as a percent relative to the control group:

$$\%\ \text{activity} = 100 \times [(\text{parasitemia control group} - \text{parasitemia treated group})/\text{parasitemia control group}]$$

The results for 1 × 30 mg/kg dose experiments were varied (Table 2). In terms of the activity of the drug, **1** did poorly when administered orally but better when given subcutaneously. **4** and **15** were opposite to this, and **22** was fairly good both orally and subcutaneously. However, the average survival time of the mice in all cases was under 10 days, indicating that even if the drug dramatically reduced the parasitemia initially, there was recrudescence. In this protocol, CQ gave similar results. Improvements were seen in some cases of the 4 × 30 mg/kg dosage experiment: **1** showed little difference, **4** showed high activity and about a 10 day increase in survival days compared to control animals, and both **15** and **22** were encouraging, with **22** resulting in two of the three treated mice being parasite-free on day 30 post-infection. The change from phenyls in **4** to pyridyls in **22** seemed to result in a drug that was orally active and showed no obvious signs of toxicity when administered to mice. **15** was a surprise in that it showed good oral activity but was

Table 2. In Vivo Data for Mice Infected with *P. berghei*, Tested at the Swiss Tropical and Public Health Institute[a]

drug	dosage (mg/kg)	route	% activity	mouse survival (days)
CQ	1 × 30	oral	99.7	9
	1 × 30	subcutaneous	99.5	10
	4 × 30	oral	99.9	23 (3/10 mice cured)
1	1 × 30	oral	< 40	mice euthanized day 3
	1 × 30	subcutaneous	92	7
	4 × 30	oral	96	8
4	1 × 30	oral	> 99.9	8
	1 × 30	subcutaneous	< 40	mice euthanized day 3
	4 × 30	oral	> 99.9	16
15	1 × 30	oral	99.7	7
	1 × 30	subcutaneous	< 40	mice euthanized day 3
	4 × 30	oral	> 99.9	20 (1/3 mice cured)
22	1 × 30	oral	94	7
	1 × 30	subcutaneous	99.3	9
	4 × 30	oral	> 99.9	27 (2/3 mice cured)

[a] Historical data for CQ is included for comparison. The no-drug controls were euthanized on day 4.

Table 3. Second in Vivo Trial against *P. berghei*, with Dosage Adjusted To Be Equimolar to 30 mg/kg CQ[a]

drug	dosage (mg/kg)	route	% activity	mouse survival (days)
CQ	4 × 30	oral	99.9	23 (3/10 mice cured)
21	4 × 44	oral	>99.9	>30 (3/3 mice cured)
22	4 × 46	oral	>99.9	30 (9/10 mice cured)

[a] Historical data for CQ are included for comparison.

poor when administered subcutaneously, even though it had a ClogP value of 8.9. It is noted that ClogP is a calculated value that gives only an indication of aqueous solubility but should not be used on its own as an equivalent to bioavailability.[23] Another possible reason for the good in vivo activity of **15** is that the trityl group was being cleaved from the rest of the molecule after oral administration. This would result in the starting material, **14**, which has a ClogP value of 3.4 (consistent with good oral activity) and low IC_{50} values against *P. falciparum* strains (Table 1).

Because of the difference in molecular weights, a dose of 30 mg/kg of CQ actually resulted in many more molecules being administered to the mouse than in a dose of 30 mg/kg of any of the RCQ compounds. Accordingly, a second in vivo experiment was carried out for **21** and **22**, wherein the dosage was adjusted such that each compound was administered in an *equimolar* amount to 30 mg/kg of CQ. In this test **22** was administered to 10 mice to obtain a more reliable evaluation of oral activity in this mammalian model (Table 3). **21** had 3 out of 3 mice cured, and **22** had 9 out of 10, with the 10th mouse reaching 29 days. Parasitemia determination on day 30 showed that the surviving mice were parasite-free.

Accumulation of 1 in the DV of *P. falciparum*. When reversal agents such as verapamil or imipramine are coadministered with CQ, the enhanced CQ activity is limited to CQR parasites; no effect is seen against CQS *P. falciparum*.[11−13] However, several of the RCQ compounds show IC_{50} values *lower* than CQ against even CQS parasites. One hypothesis to explain this enhanced potency against CQS parasites is that the RA headgroup also had antimalarial potency and that its intrinsic antimalarial effect was enhancing activity of the total RCQ molecule. To investigate this possibility, compound **26**, which lacks the quinoline moiety, was tested against both CQS and CQR *P. falciparum*. As can be seen in Table 1, **26** showed no effect up to 2500 nM, and so the RA headgroup has no strong intrinsic antimalarial activity.

A second hypothesis to explain the enhanced activity of the RCQ molecules is that there was increased accumulation in the DV of the parasite. To test this, an accumulation experiment was devised, similar to one used by Kelly et al. to show accumulation of xanthones in the DV of *Plasmodium* parasites.[24] The experimental design provides two results: first, it allows the amount of drug accumulated in the DV to be measured; second, by demonstrating that the retention time is unchanged for the released drug, it shows that the vast majority of the drug is not modified by the parasite. As shown in Figure 2, **1** accumulated in the parasitized red blood cells (PRBCs) in a manner similar to that of CQ (Figure 2) in that there was a rapid initial uptake over the first minute followed by a slow uptake until an equilibrium state was reached by about 60 min. After this time the accumulated amount remained nearly constant.

The initial concentration of **1** was slightly higher than CQ (5.5−4.9 μM), but after 1 h the concentration of **1** in the medium was lower than CQ in both the D6 and Dd2 experiments. Addition of the ammonium chloride to the PRBCs resulted in a rapid return of each drug into the culture medium (data not shown). Both **1** and CQ returned to very close to their respective starting levels, and the HPLC retention times were not changed, indicating that the chemical composition of each of the drugs was, in fact, not altered while in the PRBCs over the course of the experiment.



Figure 2. Time dependent decline of drug concentration in culture medium for each drug/*P. falciparum* strain combination. The graph shows the first 60 min. The uncertainties are estimated to be ±5% based on variations measured in multiple trials of similar experiments performed under identical experimental conditions.

Table 4. Uptake, DV Concentration, and Accumulation Ratio for Drug/*P. falciparum* Strain Combinations[a]

drug/*Pf* strain	uptake[b] (mol)	concentration in DV (mM)	Aaccumulation ratio[c]
1/D6	1.6×10^{-8}	65	32000
1/Dd2	1.8×10^{-8}	70	38000
CQ/D6	0.7×10^{-8}	29	9000
CQ/Dd2	0.5×10^{-8}	20	6000

[a] The concentration in DV is calculated assuming 6×10^7 PRBCs present and an average DV volume of 4 fL. The uncertainties are estimated to be ±5%, based on variations measured in multiple trials of similar experiments performed under identical experimental conditions. [b] Uptake is the number of moles of drug taken up by the 6×10^7 PRBCs after 1 h of incubation, calculated by the ratio [(concentration in medium after NH_4Cl addition − concentration in medium after 1 h of incubation)]/5 mL (the volume of medium used). [c] Accumulation ratio is [concentration in DV/concentration in medium].

By taking the difference between the amount of each drug in the medium after 60 min of incubation and the amount after the addition of ammonium chloride to the medium, it is possible to deduce how much of each drug was taken up by the parasites. To estimate the concentration of the drug in the DV, it was first considered that each flask contained a 50 μL pellet of red blood cells (RBCs) and that each RBC has a volume of 80 fL.[25] Therefore, each flask contained 6×10^8 cells. Given the parasitemia level was about 10%, there were 6×10^7 PRBCs present. Assuming the DV has an average volume of 4 fL,[25] the total DV volume for the population of parasites is $(6 \times 10^7) \times (4 \times 10^{-15}) = 2.5 \times 10^{-7}$ L. The concentration of each drug in the DV can then be calculated (Table 4). This calculation is based on the assumption that the drug is completely released by the ammonium chloride. However, a small portion of the drug may still be associated with heme and thus not be released to the medium.

The accumulation ratio for each drug can be estimated from these data, with the assumption that the drugs accumulate within the parasite DV; we provide evidence for this, below. From an initial medium concentration of ~5 μM, **1** accumulates in the DV of D6 *P. falciparum* to an equilibrium concentration of about 65 mM, a 13000-fold increase, yielding

Table 5. Apparent Dissociation Equilibrium Constants Obtained from Optical Titration of Heme with Antimalarial Agents, Assuming a 2:1 Heme to Drug Stoichiometry, and IC_{50} for the Inhibition of β-Hematin by RCQ Compounds

drug	K_d [μM (app)]	β-hematin inhibition (μM)
CQ	4.0	24
1	8.6	9.0
4	3.3	2.5
5	3.0	3.5
13	7.3	10
15	5.4	insoluble
17	2.5	14
21	1.0	2.0
22	1.7	1.6

an accumulation ratio ([drug in the DV]/[drug in medium at equilibrium]) of 32 000. Most significantly, the accumulation ratio of **1** is more than triple that of CQ. This is in agreement with the IC_{50} values, in that the values for CQ are well over twice those of **1**, even for CQS D6 *P. falciparum* (Table 1). However, the DV is known to swell as it accumulates quinoline-based antimalarial drugs,[26,27] and so the accumulation ratio presented here may be too large because the calculation is based on a DV volume of 4 fL. Yet whether the drug accumulation causes or is enabled by the swelling of the DV does not detract from the fact that the molar uptake of **1** is more than double that of CQ, irrespective of DV volume. In any event, these experiments were carried out at significantly higher drug concentrations than the IC_{50} determinations presented in Table 1 and may reflect mechanisms in addition to simple differences in accumulation and inhibition of hemozoin formation.[28,29] In fact, the higher concentrations may represent at least a significant portion of the CQ blood concentration time-course during malaria chemotherapy.[30,31]

In Vitro Heme Binding and β-Hematin Inhibition. It is known that CQ binds to heme dimers in vitro and also can inhibit the formation of β-hematin, the in vitro analogue of hemozoin.[32−35] A selection of RCQ compounds was tested for whether addition of the RA headgroup affected the compounds' abilities to bind to heme and to inhibit the formation of β-hematin. As can be seen from Table 5, there was no significant difference between CQ and the RCQ compounds' ability to bind heme in solution (Table 5, K_d values). Although the numbers range from 1 to 8.3 μM, they are all in the micromolar range, with CQ about in the middle. A weak, positive correlation was noted between the RCQ in vitro potency (Table 1) and its K_d value ($R^2 \approx 0.17$). **26** was tested and showed no activity, suggesting that the quinoline portion of the molecules physically interacted with the heme.

Regarding β-hematin inhibition, the IC_{50} values ranged from 24 μM for CQ to about 2 μM for **4**, **21**, and **22** (Table 5). While these are all in the micromolar range, there is a trend toward ($R^2 \approx 0.66$) enhanced potency, coinciding with lower IC_{50} values for the RCQ compounds against *P. falciparum* strains (Table 1).

Hemozoin Inhibition in Vivo. The hemozoin inhibition properties of **1** and **22** in cell culture were examined in a series of experiments, monitoring in parallel with microscopy (to characterize morphological change of the parasites) and a colorimetric assay (to provide a semiquantitative assessment of hemozoin suppression). The images obtained by microscopy show hemozoin in the control samples, and even in the 100 nM CQ samples, but compound **22**, at as low as 10 nM, appeared to preclude hemozoin formation in both D6 and Dd2 strains. **1** at 100 nM showed some hemozoin present in the D6 sample, so inhibition was not complete even at this concentration in a CQS strain. This was also the case with the CQR Dd2 stain (not shown).



Figure 3. Microscope images from showing D6 and Dd2 parasites in RBCs: (top) D6 parasites clearly showing hemozoin in the control and CQ samples and showing the enlarged DV with little or no hemozoin with **1** and **22**; (bottom) Dd2 parasites with **22**, showing little or no hemozoin formation.

The images (Figure 3) also show an enlarged DV in the parasites incubated in the presence of drugs. In the drug-free control, the DV is fairly small relative to the parasite and is almost entirely filled by several large crystals of hemozoin. It is known that the DV swells in the presence of quinoline-based antimalarial drugs,[26,27] and this can clearly be seen with both **1** and **22** (and to a lesser extent with CQ), where the almost clear DV is easy to distinguish from the darker parasite.

For the colorimetric assay, synchronized D6 and Dd2 *P. falciparum* parasites were incubated with various concentrations of each drug for 24 h, then lysed by treatment with a saponin-containing lysis buffer. The hemozoin was extracted by centrifugation, then washed with acetone and PBS buffer to remove residual protein. The pellet was then dissolved in 0.2 N sodium hydroxide solution, and the absorbance at 400 nm was measured. By use of an extinction coefficient of 91 000 cm^{-1} M^{-1}, the amount of heme was calculated.[36−38] The amount of heme per parasitized erythrocyte was calculated on the basis of the number of erythrocytes in the culture and the percent parasitemia obtained after growing synchronized culture for 24 h. Baseline hemozoin production was calculated by processing the cell culture at 0 h in an identical way.

The results from the colorimetric assays indicate that the RCQ molecules did indeed decrease the hemozoin production of *P. falciparum*, in a manner analogous to but more potently than CQ (Figure 4). At 10 nM against D6, **22** nearly completely inhibited hemozoin production. Dd2 required 100 nM **22** for the same percentage decrease, but this was much lower than the 1000 nM required by CQ.

The results for **1** against Dd2 are between those for **22** and CQ, a result consistent with the in vitro IC_{50} values (Table 1). The relatively low activity of **1** against D6 seems inconsistent with its low IC_{50} value against CQS *P. falciparum*. However, these results are for very high concentrations. While it is possible that hemozoin inhibition is not the only significant mode of action for the RCQ molecules and that the low IC_{50} value is due, in part, to another antimalarial mechanism, further investigation would be needed before such a conclusion is reached.

These in vivo hemozoin inhibition experiments indicate that the RCQ molecules act in a manner similar to that of CQ against CQS *P. falciparum*. The enlarged DV caused by accumulation of the drugs can be seen clearly, as can the



Figure 4. Graph of hemozoin production in synchronized D6 and Dd2 *P. falciparum* when incubated with various concentrations of CQ, **1**, and **22**. After the parasites were lysed, the hemozoin was collected by centrifugation, washed, and dissolved in 0.2 N sodium hydroxide solution. The absorbance at 400 nm was measured, and the amount of heme was calculated using an extinction coefficient of 91 000 cm^{-1} M^{-1} The amount of heme per parasitized erythrocyte was calculated based on the number of erythrocytes in the culture and the percent parasitemia obtained after growing synchronized culture for 24 h. Blank regions represent concentration of drug not tested for a particular cell line. Uncertainties are estimated to be at least ±15%, based on estimated uncertainties due to the extraction of hemozoin from the cells.

reduction in hemozoin production. These effects are most pronounced for **22**, requiring substantially lower concentrations than CQ to effect almost complete inhibition of hemozoin.

Summary and Conclusion

This work strongly supports the hypothesis that an improved drug can be made by combining elements of CQ and a reversal agent. The in vitro results clearly show that the RCQ compounds have great efficacy against *P. falciparum*, and the in vivo results demonstrate that the compounds are efficacious in a mouse model. In the in vivo test, **22** stands out as an excellent lead compound for full preclinical testing, with good activity via the oral route of administration, a low ClogP, and no obvious signs of toxicity. Further testing will also be carried out using a wider range of drug-resistant parasite strains to demonstrate that these compounds truly are promising lead compounds for all CQR *Plasmodia*.

While the mode of action of these compounds has not been fully elucidated, the experiments described above show that the RCQ compounds appear to act in a manner similar to that of CQ. Compound **22** showed the highest level of hemozoin inhibition, both in vitro and in vivo. Taken together, the results suggest that the addition of the RA moiety to the 4-aminoquinoline can enhance the mode of antimalarial activity, at least in part by acting to increase the accumulation in the parasite's DV.

Experimental Section

Chemistry. All chemicals were obtained from Sigma-Aldrich Chemical Co. Purities of all final products were ≥95% as determined by HPLC, measuring by UV detection at 254 and 325 nm, using a Varian ProStar 325 UV/vis dual wavelength detector. HPLC method A was done with a Microsorb-MV 100 CN 5 μm, 4.6 mm × 250 mm column, eluting with 100% methanol for 30 min unless otherwise stated. HPLC method B was performed using a SUPELCO Ascentis RP-Amide 5 μm, 4.6 mm × 150 mm column, eluting with 100% methanol for 30 min unless otherwise stated. HPLC method C was performed using a SUPELCO Ascentis C18 5 μm, 4.6 mm × 150 mm column, eluting with a 30 min gradient, from 95:5 to 5:95 water with 0.1% formic acid (v/v)/acetonitrile. High resolution mass spectrometry was performed on a Bruker micrOTOF-Q instrument. Results were obtained using electospray ionization (ESI) in the positive mode, at a flow rate of 0.4 mL/min with 1:1 methanol−water. ^{1}H, ^{13}C, and 2D NMR experiments were run on a Bruker 400 MHz AMX or AVANCE-II+ instrument, using the standard pulse sequences provided, including zg30, zgpg30 cosygpqf, hsqcetgpsi2, hmbcgplpndqf, and noesyph, at 25 °C.

The syntheses of **1**, **2b**, and **3b** have been previously described.[17]

2-(7-Chloroquinolin-4-ylamino)ethan-1-ol (2a). A mixture of 4,7-dichloroquinoline (4.95 g, 0.025 mol) and ethanolamine (15.27 g, 15.0 mL, 0.25 mol) was heated with stirring at 130−140 °C for 24 h. After cooling, the mixture was poured into water (150 mL) and filtered. After air drying, the solid was boiled in methanol (100 mL), allowed to cool to room temperature, then cooled in ice. The solid was filtered, then washed with a small amount of ice cold methanol to give **2a** (3 g, 54%) as an off-white solid. HPLC (method A) t_R = 6.99 min (99% pure). ^{1}H NMR δ (ppm) (400 MHz, CH_3OH-d_4): 3.48−3.55 (2 H, m), 3.85 (2 H, q, J = 5.80 Hz), 6.60 (1 H, d, J = 5.67 Hz), 7.43 (1 H, dd, J = 9.02, 2.20 Hz), 7.80 (1 H, d, J = 2.19 Hz), 8.11 (1 H, t, J = 9.02 Hz), 8.38 (1 H, d, J = 5.64 Hz). ^{13}C NMR δ (ppm) (100 MHz, CH_3OH-d_4): 46.2, 60.7, 99.7, 118.8, 124.3, 126.1, 127.6, 136.4, 149.7, 152.5, 152.9.

2-(7-Chloroquinolin-4-ylamino)ethyl Methanesulfonate (3a). To a suspension of **2a** (1.5 g, 6.7 mmol) in anhydrous dichloromethane (25 mL) under a nitrogen atmosphere was added triethylamine (2 mL, 14.3 mmol). The mixture was cooled to below 0 °C. Methanesulfonyl chloride (0.57 mL, 7.41 mmol) was added slowly, keeping the temperature below 5 °C, and the mixture was stirred in an ice bath for 1 h. The mixture was added to a saturated $NaHCO_3$ solution (100 mL), and the organic layer was separated and washed with saturated $NaHCO_3$ solution (25 mL). The combined aqueous layers were extracted with dichloromethane (2 × 20 mL). The combined organic extracts evaporated to leave **3a** (1.19 g, 59%) as an off-white solid.

General Procedure for the Preparation of Compounds 4−13. A mixture of the respective piperazine or homopiperazine compound (1.2 equiv), triethylamine (2.0 equiv), and appropriate methylsulfonate ester (1.0 equiv) was heated to 70 °C in THF for 3 days with stirring. After the mixture was cooled to room temperature, 50% K_2CO_3 solution was added. The mixture was shaken, and the THF layer was separated. The aqueous layer was extracted with ethyl acetate. The extracts were combined with the THF layer and washed with water. After the mixture was dried and evaporated, the residue was purified.

***N*-(2-(4-Benzhydrylpiperazin-1-yl)ethyl)-7-chloroquinolin-4-amine (4).** The title compound was prepared from 1-(diphenylmethyl)piperazine (0.4 g, 0.0016 mol), triethylamine (0.27 g, 0.0027 mol), and **3a** (0.4 g, 0.00133 mol) in THF (12 mL) according to the general procedure. The crude compound was purified by recrystallization in ethyl acetate to give an off-white solid (0.13 g, 21%). HPLC (method B) t_R = 2.74 min (97% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-d) 2.51 (8 H, d, J = 40.09 Hz), 2.78 (2 H, t, J = 5.91 Hz), 3.29 (2 H, q, J = 5.32 Hz), 4.26 (1 H, s), 5.96 (1 H, s), 6.35 (1 H, d, J = 5.36 Hz), 7.21−7.14 (2 H, m), 7.31−7.25 (4 H, m), 7.39 (1 H, dd, J = 8.90, 2.20 Hz), 7.46−7.40 (4 H, m), 7.65 (1 H, d, J = 8.92 Hz), 7.95 (1 H, d, J = 2.16 Hz), 8.52 (1 H, d, J = 5.31 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-d) 38.9, 52.1, 52.9, 55.4, 76.2, 99.3, 117.4, 121.1,

125.3, 127.0, 127.9, 128.5, 128.8, 134.8, 142.6, 149.1, 149.8, 152.2. MS (ESI): m/z 457.2149 M + H (calculated 457.2154).

***N*-(3-(4-Benzhydrylpiperazin-1-yl)propyl)-7-chloroquinolin-4-amine (5).** The title compound was prepared from 1-(diphenylmethyl)piperazine (0.56 g, 0.0022 mol), triethylamine (0.43 g, 0.0042 mol), and **3b** (0.65 g, 0.0021 mol) in THF (15 mL) according to the general procedure. The crude compound was purified by recrystallization in ethyl acetate to give an off-white solid (0.32 g, 31%). HPLC (method B) t_R = 3.22 min (97% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*) 1.97−1.89 (2 H, m), 2.87−2.32 (10 H, m), 3.35 (2 H, q, J = 5.12 Hz), 4.42 (1 H, s), 6.29 (1 H, d, J = 5.40 Hz), 7.13 (1 H, dd, J = 8.92, 2.18 Hz), 7.28−7.20 (2 H, m), 7.36−7.29 (4 H, m), 7.46−7.41 (4 H, m), 7.61 (1 H, s), 7.78 (1 H, d, J = 8.95 Hz), 7.92 (1 H, d, J = 2.16 Hz), 8.48 (1 H, d, J = 5.35 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*) 23.3, 44.5, 51.6, 54.0, 58.9, 75.9, 98.4, 117.5, 122.4, 124.6, 127.2, 128.2, 128.5, 128.6, 134.6, 141.9, 149.1, 150.6, 152.2. MS (ESI): m/z 471.2293 M + H (calculated 471.2310).

***N*-(3-(4-Benzhydryl-1,4-diazepan-1-yl)propyl)-7-chloroquinolin-4-amine (6).** The title compound was prepared from **27** (0.22 g, 0.001 mol), triethylamine (0.18 g, 0.0018 mol), and **3b** (0.20 g, 0.0006 mol) in THF (15 mL) according to the general procedure. The crude compound was purified by chromatography on alumina, eluting with ethyl acetate/hexanes 40:60) to give a solid (0.07 g, 24%). HPLC (method C) t_R = 10.76 min (95% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*): 1.85−1.86 (4 H, m), 2.72−2.73 (6 H, m), 2.78 (2 H, d, J = 6.40 Hz), 2.87 (2 H, t, J = 5.56 Hz), 3.34 (2 H, q, J = 5.22 Hz), 4.63 (1 H, s), 6.29 (1 H, d, J = 5.39 Hz), 7.18−7.20 (2 H, m), 7.27−7.27 (5 H, m), 7.43 (4 H, d, J = 7.75 Hz), 7.62 (1 H, s), 7.72 (1 H, d, J = 8.92 Hz), 7.92 (1 H, d, J = 2.18 Hz), 8.48 (1 H, d, J = 5.34 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*): 24.5, 27.8, 44.5, 52.9, 53.0, 54.3, 57.0, 57.9, 75.7, 98.5, 117.6, 122.1, 124.8, 127.0, 128.0, 128.5, 128.6, 134.6, 143.2, 149.2, 150.6, 152.2. MS (ESI): m/z 485.2454 M + H (calculated 485.2467).

7-Chloro-*N*-(2-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethyl)quinolin-4-amine (7). The title compound was prepared from 1-[(4-chlorophenyl)(phenyl)methyl]piperazine (0.46 g, 0.0016 mol), triethylamine (0.27 g, 0.0027 mol), and **3a** (0.4 g, 0.00133 mol) in THF (12 mL) according to the general procedure. The crude compound was purified by recrystallization in ethyl acetate to give an off-white solid (0.32 g, 31%). The crude compound was purified by recrystallization in ethyl acetate/hexanes (70/30) to give an off-white solid (0.20 g, 30%). HPLC (method A) t_R = 7.30 min (96% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*) 2.50 (8 H, d, J = 44.37 Hz, 2.78 (2 H, t, J = 5.91 Hz), 3.29 (2 H, q, J = 5.32 Hz), 4.24 (1 H, s), 5.94 (1 H, s), 6.35 (1 H, d, J = 5.36 Hz), 7.31−7.19 (5 H, m), 7.41−7.35 (5 H, m), 7.64 (1 H, d, J = 8.93 Hz), 7.95 (1 H, d, J = 2.16 Hz), 8.52 (1 H, d, J = 5.31 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*) 38.9, 52.0, 52.8, 55.4, 75.4, 99.3, 117.3, 121.1, 125.3, 127.2, 127.8, 128.6, 128.7, 128.8, 129.1, 132.6, 134.8, 141.2, 142.1, 149.1, 149.7, 152.1. MS (ESI): m/z 491.1745 M + H (calculated 491.1764).

7-Chloro-*N*-(3-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)propyl)quinolin-4-amine (8). The title compound was prepared from 1-[(4-chlorophenyl)(phenyl)methyl]piperazine (0.63 g, 0.0022 mol), triethylamine (0.43 g, 0.0042 mol), and **3b** (0.65 g, 0.0021 mol) in THF (15 mL) according to the general procedure. The crude compound was purified by recrystallization from ethyl acetate to give an off-white solid (0.38 g, 34%). HPLC (method A, 40 min) t_R = 9.67 min (98% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*) 1.92 (2 H, p, J = 5.38 Hz), 2.70−2.52 (10 H, m), 3.34 (2 H, q, J = 5.11 Hz), 4.37 (1 H, s), 6.29 (1 H, d, J = 5.40 Hz), 7.15 (1 H, dd, J = 8.90, 2.17 Hz), 7.32−7.22 (3 H, m), 7.38−7.30 (2 H, m), 7.42−7.35 (4 H, m), 7.52 (1 H, s), 7.76 (1 H, d, J = 8.95 Hz), 7.92 (1 H, d, J = 2.15 Hz), 8.48 (1 H, d, J = 5.35 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*) 23.3, 44.4, 51.6, 53.9, 58.8, 75.3, 98.4, 117.4, 122.3, 124.6, 127.5, 128.1, 128.6, 128.7, 129.3, 132.7, 134.6, 140.8, 141.2, 149.1, 150.5, 152.2. MS (ESI): m/z 505.1911 M + H (calculated 505.1920).

7-Chloro-*N*-(3-(4-((4-chlorophenyl)(phenyl)methyl)-1,4-diazepan-1-yl)propyl)quinolin-4-amine (9). The title compound was prepared from **28** (0.17 g, 0.000 57 mol), triethylamine (0.18 g, 0.0018 mol), and **3b** (0.20 g, 0.000 64 mol) in THF (15 mL) according to the general procedure. The crude compound was purified by chromatography on alumina, eluting with ethyl acetate/hexanes (40:60) to give a solid (0.21 g, 71%). HPLC (method B) t_R = 4.66 min (97% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*) 1.81−1.92 (4 H, m), 2.74−2.75 (8 H, m), 2.88 (2 H, t, J = 5.53 Hz), 3.37 (2 H, q, J = 5.13 Hz), 4.61 (1 H, s), 6.31 (1 H, d, J = 5.41 Hz), 7.26−7.28 (5 H, m), 7.35−7.40 (4 H, m), 7.53 (1 H, s), 7.72 (1 H, d, J = 8.93 Hz), 7.93 (1 H, d, J = 2.16 Hz), 8.50 (1 H, d, J = 5.36 Hz). MS (ESI): m/z 519.2079 M + H (calculated 519.2077).

***N*-(3-(4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)propyl)-7-chloroquinolin-4-amine (10).** The title compound was prepared from 1-(bis(4-fluorophenyl)methyl)piperazine (0.52 g, 0.0018 mol), triethylamine (0.20 g, 0.0019 mol), and **3b** (0.41 g, 0.0013 mol) in THF (15 mL) according to the general procedure. The crude compound was purified by chromatography on alumina, eluting with ethyl acetate/hexanes (40:60) to give a solid (0.12 g, 18%). HPLC (method B) t_R = 3.3 min (98% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*) 1.97 (3 H, m), 2.57 (8 H, bs), 2.68 (3 H, t, J = 5.60 Hz), 3.40 (3 H, m), 4.38 (1 H, s), 6.34 (1 H, d, J = 5.47 Hz), 7.04 (4 H, t, J = 8.55 Hz), 7.22 (1 H, dd, J = 8.90, 2.05 Hz), 7.40 (4 H, dd, J = 8.47, 5.45 Hz), 7.67 (1 H, bs), 7.84 (1 H, d, J = 8.89 Hz), 8.00 (1 H, s), 8.51 (1 H, d, J = 5.44 Hz).

***N*-(2-(4-(9*H*-Fluoren-9-yl)-1,4-diazepan-1-yl)ethyl)-7-chloroquinolin-4-amine (11).** The title compound was prepared from **29** (0.24 g, 0.0010 mol), triethylamine (0.69 g, 0.0068 mol), and **3a** (0.30 g, 0.0010 mol) in THF (15 mL) according to the general procedure. The crude compound was purified by chromatography on alumina, eluting with ethyl acetate/hexanes (40:60) to give a solid (0.05 g, 11%). HPLC (method C) t_R = 10.88 min (95% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*): 1.79−1.80 (2 H, m), 2.67−2.70 (2 H, m), 2.74−2.78 (2 H, m), 2.84 (2 H, t, J = 5.93 Hz), 2.91 (4 H, dt, J = 12.45, 5.98 Hz), 3.23 (2 H, q, J = 5.25 Hz), 4.90 (1 H, s), 6.17 (1 H, s), 6.34 (1 H, d, J = 5.34 Hz), 7.26 (2 H, s), 7.37 (3 H, d, J = 7.82 Hz), 7.63 (1 H, s), 7.69 (3 H, d, J = 7.26 Hz), 7.96 (1 H, d, J = 2.18 Hz), 8.52 (1 H, d, J = 5.28 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*): 29.4, 39.7, 53.4, 54.9, 56.5, 71.6, 99.3, 119.8, 121.2, 125.3, 125.5, 127.1, 128.1, 128.8, 134.8, 140.8, 144.9, 149.1, 149.9, 152.1. MS (ESI): m/z 469.2143 M + H (calculated 469.2154).

***N*-(3-(4-(9*H*-Fluoren-9-yl)-1,4-diazepan-1-yl)propyl)-7-chloroquinolin-4-amine (12).** The title compound was prepared from **29** (0.31 g, 0.0012 mol), triethylamine (0.25 g, 0.0025 mol), and **3b** (0.37 g, 0.0012 mol) in THF (15 mL) according to the general procedure. The crude compound was purified by chromatography on alumina, eluting with ethyl acetate/hexanes (40:60) to give a solid (0.29 g, 50%). HPLC (method C) t_R = 11.24 min (97% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*): 1.88−1.93 (4 H, m), 2.08 (1 H, s), 2.77 (3 H, s), 2.83 (2 H, t, J = 5.89 Hz), 2.94 (2 H, t, J = 5.29 Hz), 3.00 (1 H, s), 3.34 (2 H, t, J = 5.75 Hz), 4.92 (1 H, s), 6.27 (1 H, d, J = 5.53 Hz), 7.38 (2 H, t, J = 7.47 Hz), 7.64 (2 H, d, J = 7.49 Hz), 7.69 (2 H, d, J = 7.56 Hz), 7.96−7.96 (2 H, m), 8.48 (1 H, s). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*): 23.3, 24.1, 27.6, 43.5, 50.2, 51.7, 53.5, 56.8, 57.4, 71.3, 98.3, 117.5, 119.9, 122.7, 125.1, 125.5, 127.2, 127.7, 128.3, 135.0, 140.9, 144.5, 148.3, 151.0, 151.3, 177.3. MS (ESI): m/z 483.2297 M + H (calculated 483.2310).

***N*^{1}-(7-chloroquinolin-4-yl)-*N*^{2}-(3-(10,11-dihydro-5*H*-dibenzo[*b*,*f*]azepin-5-yl)propyl)-*N*^{2}-methylethane-1,2-diamine (13).** Desipramine hydrochloride (0.44 g, 0.00145 mol) was dissolved in water (7 mL), and solid $NaHCO_3$ (0.24 g, 0.0029 mol) was added with stirring. After addition of dichloromethane (8 mL), two clear layers resulted. The aqueous layer was removed and extracted with dichloromethane (2 × 7 mL). The combined

organic layers were evaporated to leave desipramine free base as a yellow oil. To this oil were added anhydrous THF (12 mL) and **3a** (0.35 g, 0.001 16 mol) followed by triethylamine (0.32 mL, 0.002 32 mol). After being stirred at 50−60 °C for 72 h, the mixture was allowed to cool to room temperature. The mixture was diluted with 50% K_2CO_3 solution (30 mL), and the THF layer was separated. The aqueous layer was extracted with ethyl acetate (2 × 10 mL). The extracts were combined with the THF layer and washed with water (10 mL). After the mixture was dried and evaporated, the residue was chromatographed on alumina (MCB type F20, 80−200 mesh), eluting with ethyl acetate:/hexanes (70:30) to give a yellow oil (0.42 g, 77%). HPLC (method A) t_R = 9.12 min (96% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*): 1.78 (2 H, p, *J* = 6.79 Hz), 2.23 (3 H, s), 2.46 (2 H, t, *J* = 7.00 Hz), 2.68 (2 H, t, *J* = 5.81 Hz), 3.03 (4 H, s), 3.26−3.16 (2 H, m), 3.79 (2 H, t, *J* = 6.54 Hz), 5.82 (1 H, s), 6.32 (1 H, d, *J* = 5.35 Hz), 6.84 (2 H, td, *J* = 7.14, 1.61 Hz), 7.09−6.95 (6 H, m), 7.23 (1 H, dd, *J* = 8.90, 2.19 Hz), 7.44 (1 H, d, *J* = 8.93 Hz), 7.95 (1 H, d, *J* = 2.16 Hz), 8.52 (1 H, d, *J* = 5.31 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*): 24.7, 31.0, 38.5, 40.9, 47.0, 53.3, 54.3, 98.2, 116.3, 118.6, 120.0, 121.5, 124.3, 125.3, 127.7, 128.8, 133.1, 133.7, 147.0, 148.1, 148.6, 151.0. MS (ESI): *m*/*z* 471.2316 M + H (calculated 471.2310).

7-Chloro-*N*-(3-(piperazin-1-yl)propyl)quinolin-4-amine (14). 2b (2.7 g, 0.0116 mol) was finely ground and suspended in dry THF (50 mL). Triethylamine (2.9 g, 0.29 mol) was added, and the mixture was cooled to below 0 °C. Methanesulfonyl chloride (1.46 g, 0.0128 mol) was added slowly, keeping the temperature below 5 °C. After the mixture was stirred in an ice bath for 1 h, TLC (alumina plate, run in ethyl acetate) indicated no **2b** left in the mixture. Piperazine (10 g, 0.116 mol) was added, and the mixture was heated to reflux. After 2 h TLC indicated the reaction was complete, and the mixture was allowed to cool to room temperature. Then 150 mL of saturated $NaHCO_3$ solution was added and the solution was extracted with ethyl acteate (3 × 50 mL). The combined organic extracts were washed with water (5 × 25 mL), dried, and evaporated to give a cream solid (1.2 g, 34%). HPLC (method C) t_R = 2.81 min (93% pure). ^{1}H NMR δ (ppm) (400 MHz, CH_3OH-d_4): 1.79−1.89 (2 H, m), 2.38−2.49 (6 H, m), 2.76−2.83 (4 H, m), 3.33 (2 H, t, *J* = 6.79 Hz), 6.44 (1 H, d, *J* = 5.69 Hz), 7.27−7.33 (1 H, m), 7.68 (1 H, d, *J* = 2.18 Hz), 7.98 (1 H, d, *J* = 9.01 Hz), 8.25 (1 H, d, *J* = 5.65 Hz). ^{13}C NMR δ (ppm) (100 MHz, CH_3OH-d_4): 25.8, 42.6, 46.1, 54.6, 58.0, 99.6, 118.7, 124.3, 126.0, 127.6, 136.4, 149.6, 152.4, 152.8. MS (ESI): *m*/*z* 305.1538 M + H (calculated 305.1528).

7-Chloro-*N*-(3-(4-tritylpiperazin-1-yl)propyl)quinolin-4-amine (15). 14 (0.3 g, 0.000 98 mol) was dissolved in acetonitrile (15 mL), and potassium carbonate (0.2 g, 0.0015 mol) was added, followed by trityl chloride (0.25 g, 0.000 89 mol). The mixture was heated to reflux with stirring for 3 h, after which TLC indicated completion. After cooling to room temperature, the mixture was poured into water (50 mL) and ethyl acetate (20 mL) was added. The insoluble precipitate was filtered, washed with water and ethyl acetate, and dried. The ethyl acetate layer was separated and the aqueous layer extracted with ethyl acetate (2 × 20 mL). The combined organic phases were dried, filtered through an alumina plug, and evaporated. The residue was combined with the insoluble solid from above to give a white solid (0.15 g, 31%). HPLC (method A) t_R = 8.63 min (97% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*): 1.90−1.97 (4 H, m), 2.53 (2 H, bs), 2.67−2.72 (2 H, m), 3.06 (2 H, bs), 3.16 (2 H, bs), 3.31 (2 H, q, *J* = 4.99 Hz), 6.22 (1 H, d, *J* = 5.41 Hz), 6.62 (1 H, dd, *J* = 8.95, 2.19 Hz), 7.26−7.34 (10 H, m), 7.52 (6 H, bs), 7.67 (1 H, s), 7.84 (1 H, d, *J* = 2.16 Hz), 8.43 (1 H, d, *J* = 5.35 Hz). ^{13}C NMR δ (ppm) (100 MHz, CH_3OH-d_4): 22.8, 44.7, 47.8, 54.6, 59.6, 98.1, 117.2, 122.1, 125.0, 126.4, 127.2, 127.7, 127.8, 127.9, 129.4, 134.8, 146.9, 150.8, 151.5. MS (ESI): *m*/*z* 547.2637 M + H (calculated 547.2623).

General Method for the Preparation of Compounds 16 and 17. **14** (0.5 g, 0.001 64 mol) and the respective carbonyl compound were mixed together in dry THF (5 mL) and then treated with sodium triacetoxyborohydride (0.52 g, 0.0025 mol) followed by acetic acid (0.1 g, 0.001 75 mol).[19] The mixture was stirred under nitrogen and at room temperature for 7 days. The reaction was quenched with saturated $NaHCO_3$ solution (50 mL) and extracted into dichloromethane (3 × 10 mL). The extracts were washed with brine (10 mL), then dried and evaporated. The residue was chromatographed to give pure product.

7-Chloro-*N*-(3-(4-(2,2-diphenylethyl)piperazin-1-yl)propyl)-quinolin-4-amine (16). The title compound was prepared from diphenylacetaldehyde (0.32 g, 0.001 64 mol) according to the general procedure. The crude compound was purified by chromatography on silica, eluting with ethyl acetate/ammonium hydroxide (99:1) to give an off-white solid (0.43 g, 54%). HPLC (method A) t_R = 7.87 min (98% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*): 1.87−1.94 (2 H, m), 2.48−2.62 (6 H, m), 2.64 (4 H, s), 3.07 (2 H, d, *J* = 7.54 Hz), 3.34 (2 H, q, *J* = 5.12 Hz), 4.24 (1 H, t, *J* = 7.52 Hz), 6.30 (1 H, d, *J* = 5.41 Hz), 7.17−7.23 (2 H, m), 7.24−7.33 (9 H, m), 7.58 (1 H, s), 7.87 (1 H, d, *J* = 8.94 Hz), 7.93 (1 H, d, *J* = 2.15 Hz), 8.49 (1 H, d, *J* = 5.36 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*): 23.3, 44.5, 48.9, 53.5, 53.6, 58.8, 63.8, 98.5, 117.5, 122.5, 124.6, 126.3, 128.2, 128.4, 128.7, 134.6, 143.7, 149.1, 150.6, 152.2. MS (ESI): *m*/*z* 485.2479 M + H (calculated 485.2467).

***N*-(3-(4-(Adamant-2-yl)piperazin-1-yl)propyl)-7-chloroquinolin-4-amine (17).** The title compound was prepared from 2-adamantanone (0.5 g, 0.003 28 mol) according to the general procedure. The crude compound was purified by chromatography on silica, eluting with ethyl acetate/ammonium hydroxide (99.3:0.7) to give an off white solid (0.33 g, 46). HPLC (method A) t_R = 11.75 min (96% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*): 1.42 (2 H, d, *J* = 11.72 Hz), 1.79 (5 H, m), 1.86−2.02 (5 H, m), 2.10 (5 H, m,), 2.60−2.66 (10 H, m), 3.38 (2 H, q, *J* = 5.12 Hz), 6.31 (1 H, d, *J* = 5.41 Hz), 7.32 (1 H, dd, *J* = 8.95, 2.14 Hz), 7.81 (1 H, s), 7.91−7.95 (2 H, m), 8.50 (1 H, d, *J* = 5.37 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*): 23.2, 27.3, 27.6, 29.0, 31.4, 37.3, 37.8, 44.7, 49.7, 54.3, 59.0, 68.3, 98.4, 117.5, 122.7, 124.7, 128.6, 134.6, 149.2, 150.7, 152.2. MS (ESI): *m*/*z* 439.2631 M + H (calculated 439.2623).

***N*-(Dipyridin-2-ylmethylene)piperidin-4-amine (18).** 2,2′-Dipyridylketone (25.95 g, 0.141 mol) was dissolved in toluene (500 mL), and 4-aminopiperidine (16.2 g, 0.162 mol) was added followed by *p*-toluenesulfonic acid (∼0.5 g). The mixture was heated to reflux for 3 days, with a Dean and Stark trap to remove water. After the mixture was cooled to room temperature, the toluene was removed to leave a crude oil (37.5 g, 99%), which was used without further purification.

7-Chloro-*N*-(2-(4-(dipyridin-2-ylmethyleneamino)piperidin-1-yl)-ethyl)quinolin-4-amine (19). 18 (1.74 g, 0.0065 mol crude) was dissolved in acetonitrile (20 mL), and **3a** (1.31 g, 0.004 36 mol) and K_2CO_3 (1.2 g, 0.008 71 mol) were added. The mixture was stirred at 70 °C for 2 days. After the mixture was cooled to room temperature, water (100 mL) was added and the mixture was stirred for 30 min. The solid was filtered, washed with water, and recrystallized from toluene/hexanes twice to give a solid (0.68 g, 33%). HPLC (method A) t_R = 7.80 min (99% pure). MS (ESI): *m*/*z* 471.2054 M + H (calculated 471.2058).

7-Chloro-*N*-(3-(4-(dipyridin-2-ylmethyleneamino)piperidin-1-yl)-propyl)quinolin-4-amine (20). 18 (1.02 g, 0.003 82 mol crude) was dissolved in acetonitrile (12 mL), and **3b** (1 g, 0.003 18 mol) and K_2CO_3 (0.88 g, 0.006 36 mol) were added. The mixture was stirred at 70 °C overnight. TLC (alumina plate, run in ethyl acetate/methanol 9:1) indicated some **3b** was still present, so a further solution of **18** (0.25 g, 0.000 954 mol) in acetonitrile (5 mL) was added, and heating continued overnight. After the mixture was cooled to room temperature, the solvent was evaporated and the residue was slurried in water (30 mL). The solid was filtered, washed with water, and recrystallized from toluene/hexanes. The solid was dissolved in ethyl acetate/methanol 50:50 and stirred with alumina and charcoal for 30 min. After filtration through Celite, the solvents were removed to give

a solid (0.78 g, 50%). HPLC (method B) t_R = 2.41 min (96% pure). MS (ESI): m/z 485.2230 M + H (calculated 485.2215).

7-Chloro-*N*-(2-(4-(dipyridin-2-ylmethylamino)piperidin-1-yl)-ethyl)quinolin-4-amine (21). 19 (0.53 g, 0.001 13 mol) was dissolved in methanol (40 mL) and cooled in an ice/water bath. Sodium borohydride (0.13 g, 0.003 38 mol) was added in portions, and the mixture was stirred overnight at room temperature. After evaporation of the methanol, water (40 mL) was added to the residue, and the resulting suspension was stirred for 30 min. The mixture was extracted with dichloromethane (3 × 20 mL), and the combined extracts were washed with water (10 mL), then dried and evaporated. Chromatography on alumina, eluting with dichloromethane/methanol (95:5), gave an oil (0.17 g, 34%). HPLC (method B) t_R = 2.30 min (84% pure). ^{1}H NMR δ (ppm) ($CHCl_3$-*d*): 1.50−1.62 (2 H, m), 1.83 (1 H, s), 1.95 (2 H, d, J = 13.24 Hz), 2.04 (2 H, t, J = 11.64 Hz), 2.44−2.53 (1 H, m), 2.71 (2 H, t, J = 5.88 Hz), 2.89 (2 H, d, J = 11.30 Hz), 3.26 (2 H, q, J = 5.27 Hz), 5.24 (1 H, s), 6.09 (1 H, s), 6.34 (1 H, d, J = 5.37 Hz), 7.14 (2 H, ddd, J = 7.48, 4.87, 1.18 Hz), 7.36 (1 H, dd, J = 8.89, 2.19 Hz), 7.42 (2 H, dt, J = 7.88, 1.05 Hz), 7.62 (2 H, td, J = 7.67, 1.83 Hz), 7.64 (1 H, d, J = 8.94 Hz), 7.94 (1 H, d, J = 2.17 Hz), 8.51 (1 H, d, J = 5.32 Hz), 8.56 (2 H, ddd, J = 4.89, 1.81, 0.92 Hz). ^{13}C NMR δ (ppm) ($CHCl_3$-*d*): 33.0, 39.0, 51.9, 52.7, 55.3, 66.2, 99.2, 117.3, 121.2, 122.2, 122.4, 125.4, 128.7, 134.8, 136.7, 149.1, 149.2, 149.8, 152.1, 161.6. MS (ESI): m/z 473.2227 M + H (calculated 473.2215).

7-Chloro-*N*-(3-(4-(dipyridin-2-ylmethylamino)piperidin-1-yl)-propyl)quinolin-4-amine (22). 20 (0.60 g, 0.001 24 mol) was dissolved in methanol (40 mL) and cooled in ice. Sodium borohydride (0.14 g, 0.0037 mol) was added in portions, and the mixture was stirred at room temperature overnight. After evaporation of the methanol, the residue was stirred with water (50 mL) for 30 min and then extracted with dichloromethane (3 × 20 mL). The extracts were washed with water (20 mL), dried, and evaporated to give a solid (0.59 g, 99%). HPLC (method B) t_R = 2.49 min (97% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*): 1.57−1.70 (2 H, m), 1.87−1.95 (2 H, m), 1.99 (5 H, d, J = 11.77 Hz), 2.56 (2 H, t, J = 5.17 Hz), 2.59−2.68 (1 H, m), 3.00 (2 H, d, J = 11.29 Hz), 3.35 (2 H, q, J = 5.10 Hz), 5.25 (1 H, s), 6.29 (1 H, d, J = 5.42 Hz), 7.16 (2 H, ddd, J = 7.47, 4.88, 1.19 Hz), 7.44 (1 H, dd, J = 8.91, 2.18 Hz), 7.47 (2 H, d, J = 7.89 Hz), 7.65 (2 H, td, J = 7.67, 1.83 Hz), 7.74 (1 H, s), 7.84 (1 H, d, J = 8.96 Hz), 7.91−7.94 (1 H, m), 8.49 (1 H, d, J = 5.37 Hz), 8.59 (2 H, ddd, J = 4.89, 1.80, 0.92 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*): 23.7, 33.1, 44.5, 52.8, 53.1, 58.7, 66.5, 98.3, 117.6, 122.2, 122.4, 122.4, 125.0, 128.5, 134.6, 136.7, 149.1, 149.1, 150.7, 152.1, 162.1. MS (ESI): m/z 487.2355 M + H (calculated 487.2371).

2-(4-(4-Benzhydrylpiperazin-1-yl)butyl)isoindoline-1,3-dione (23). A mixture of *N*-(4-bromobutyl)phthalimide (0.5 g, 0.001 77 mol), 1-(diphenylmethyl)piperazine (0.47 g, 0.001 86 mol), and K_2CO_3 (0.61 g, 0.004 43 mol) was stirred and heated in acetonitrile (25 mL) to reflux for 3 h.[39] After the mixture was cooled, the acetonitrile was evaporated and the residue partitioned between water (20 mL) and ethyl acetate (20 mL). The aqueous layer was extracted with ethyl acetate (2 × 10 mL) and the combined organic layers were dried and evaporated to give a solid (0.74 g, 92%), which was used without further purification.

4-(4-Benzhydrylpiperazin-1-yl)butan-1-amine (24). 23 (0.74 g, 0.001 63 mol crude) was dissolved in ethanol (5 mL), and hydrazine hydrate (0.25 g, 0.0049 mol) was added.[39] The mixture was stirred and heated to reflux for 3 h, then allowed to cool to room temperature. The solid was filtered off, and the filter cake was washed with cold ethanol. The filtrate was evaporated to give an oil (0.53 g, ~100%), which solidified on contact with air. This was used without further purification.

***N*-(4-(4-Benzhydrylpiperazin-1-yl)butyl)-7-chloroquinolin-4-amine (25).** 4,7-Dichloroquinoline (0.24 g, 0.0012 mol) was dissolved in ethanol (10 mL), and **24** (0.53 g, 0.001 63 mol crude) was added, followed by triethylamine (0.33 g, 0.003 26 mol). The mixture was stirred and refluxed for 10 days, then allowed to cool to room temperature. The ethanol was evaporated, and the residue was partitioned between saturated $NaHCO_3$ solution (20 mL) and dichloromethane (20 mL). The organic layer was separated, and the aqueous layer was extracted with dichloromethane (2 × 20 mL). The combined dichloromethane layers were washed with saturated $NaHCO_3$ solution (20 mL), then dried and evaporated. The resulting oil was chromatographed on silica, eluting with ethyl acetate/triethylamine (99:1), to give an off-white solid (0.10 g, 17%). HPLC (method B) t_R = 2.97 min (95% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*): 1.67 (2 H, t, J = 6.86 Hz), 1.80 (2 H, p, J = 6.95 Hz), 2.37−2.54 (10 H, m), 3.24−3.33 (2 H, m), 4.19−4.24 (1 H, m), 5.38 (1 H, s), 6.38 (1 H, t, J = 6.53 Hz), 7.14−7.22 (2 H, m), 7.25−7.31 (4 H, m), 7.32 (1 H, dd, J = 8.92, 2.20 Hz), 7.41 (4 H, d, J = 7.61 Hz), 7.66 (1 H, d, J = 8.94 Hz), 7.95 (1 H, d, J = 2.18 Hz), 8.52 (1 H, d, J = 5.36 Hz). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*): 24.7, 26.4, 43.2, 51.8, 53.5, 57.7, 76.2, 99.0, 117.2, 121.1, 125.1, 127.0, 127.9, 128.5, 128.9, 134.8, 142.6, 149.2, 149.7, 152.1. MS (ESI): m/z 485.2456 M + H (calculated 485.2467).

2-(4-Benzhydrylpiperazin-1-yl)ethanol (26). 1-(2-Hydroxyethyl)-piperazine (2 g, 0.0154 mol) was dissolved in DMF (20 mL), and potassium carbonate (4.27 g, 0.0308 mol) was added, followed by a catalytic amount of potassium iodide. The mixture was stirred at room temperature, and chlorodiphenylmethane (3.12 g, 0.0154 mol) was added dropwise. After the addition, the mixture was stirred for a further 2 h at room temperature, then warmed to 70 °C, and held there overnight. After the mixture was cooled to room temperature, water (100 mL) was added, and the mixture was extracted with diethyl ether (3 × 20 mL). The combined organic extracts were washed with brine solution (30 mL), then dried and evaporated to give an oil (1.7 g, 37%). HPLC (method B) t_R = 2.25 min (95% pure). ^{1}H NMR δ (ppm) (400 MHz, $CHCl_3$-*d*): 2.43 (5 H, bs, J = 8.59 Hz), 2.54 (5 H, m, J = 5.45 Hz), 3.58 (2 H, t, J = 5.41 Hz), 4.22 (1 H, s), 7.14−7.19 (2 H, m), 7.24−7.30 (4 H, m), 7.38−7.43 (4 H, m). ^{13}C NMR δ (ppm) (100 MHz, $CHCl_3$-*d*): 52.0, 53.1, 57.7, 59.1, 76.2, 126.9, 127.9, 128.5, 142.7.

General Method for the Preparation of Compounds 27−29. The halo compound was placed in chloroform, and homopiperazine was added. The mixture was stirred and heated at reflux for 3 days. After the mixture was cooled to room temperature, a saturated $NaHCO_3$ solution was added and the mixture was shaken. The organic layer was separated and washed with water. The aqueous layers were combined with the $NaHCO_3$ layer and extracted with dichloromethane. The combined organic layers were dried and evaporated.

1-Benzhydryl-1,4-diazepane (27). The title compound was prepared from chlorodiphenylmethane (0.61 g, 0.003 mol) and homopiperazine (1.5 g, 0.015 mol) according to the general procedure. The crude compound was purified by chromatography on alumina, eluting with chloroform/methanol (95:5) to give an oil (0.35 g, 44%).

1-((4-Chlorophenyl)(phenyl)methyl)-1,4-diazepane (28). The title compound was prepared from chloro(4-chlorophenyl)phenylmethane (0.71 g, 0.003 mol) and homopiperazine (1.5 g, 0.015 mol) according to the general procedure. The crude compound was purified by chromatography on alumina, eluting with chloroform/methanol (95:5) to give an oil (0.39 g, 43%).

1-(9*H*-Fluoren-9-yl)-1,4-diazepane (29). The title compound was prepared from 9-bromofluorene (1.47 g, 0.006 mol) and homopiperazine (3 g, 0.03 mol) according to the general procedure. The crude compound was purified by chromatography on alumina, eluting with chloroform/methanol (95:5) to give an oil (0.55 g, 37%).

Inhibition of *P. falciparum* Growth. CQS (D6) and CQR (Dd2 and 7G8) *P. falciparum* maintained continuously in culture were used.[40] Asynchronous cultures were diluted with uninfected RBCs and complete medium (RPMI-1640 with 0.5% Albumax II) to achieve 0.2% parasitemia and 2% hematocrit. In 96-well microplates, CQ (positive control) or RCQ diluted in complete medium from 10 mM stock in DMSO was added to the cell

mixture to yield triplicate wells with drug concentrations ranging from 0 to 10^{-4} M in a final well volume of 100 μL. After 72 h of incubation under standard culture conditions, plates were harvested and read by the SYBR Green I fluorescence-based method[40] using a 96-well fluorescence plate reader (Gemini-EM, Molecular Devices), with excitation and emission wavelengths at 497 and 520 nm, respectively. The fluorescence readings were plotted against log [drug], and the IC_{50} values were obtained from curve fitting performed by nonlinear regression using either Prism (GraphPad) or Excel (Microsoft) software. In order to better compare results run on different days and with different batches of each stain, CQ was run as a positive control. All results obtained were "normalized" to the CQ values of 6.9 nM for D6, 102 nM for Dd2, and 108 nM for 7G8. The normalization for D6 strains, using the CQ value of 6.9 nM as the control value is shown below:

$$\text{normalized } IC_{50}(\text{RCQ compound (D6)}) = [6.9/IC_{50}(\text{CQ (D6)})] \times IC_{50}(\text{RCQ compound (D6)})$$

Mouse Efficacy against *P. berghei*. Compounds were formulated in a solution consisting of 70% Tween-80 (d = 1.08 g/mL) and 30% ethanol (d = 0.81 g/mL), followed by a 10-fold dilution in water. On day 0, heparinized blood (containing 100 μL of 200 u/mL heparin) was taken from a donor NMRI mouse with approximately 30% parasitemia. The blood was diluted in physiological saline to 10^8 parasitized erythrocytes per milliliter. From this suspension 0.2 mL was injected intravenously (iv) into experimental groups of three female NMRI mice and a control group of five mice. Compounds were administered in a volume of 10 mL/kg either as single dose 24 h after infection (day 1) either by oral gavage (po) or subcutaneous injection or as four consecutive daily po doses 4, 24, 48, and 72 h after infection (days 0−3).

On day 3 (with the single-dose regimen) or on day 4 (with the quadruple-dose regimen), 1 μL of tail blood was taken and dissolved in 1 mL of PBS buffer. Parasitemia was determined with a FACScan (Becton Dickinson) by counting 100 000 RBCs. The difference between the mean value of the control group and those of the experimental groups was calculated and expressed as a percent relative to the control group (= activity). Animals receiving no compound would die typically 5−6 days postinfection and were therefore euthanized right after determination of parasitemia. The survival of the animals was monitored up to 30 days. Mice surviving for 30 days were checked for parasitemia and subsequently euthanized. A compound was considered curative if the animal survived to 30 days postinfection with no detectable parasites by microscopy, with a detection limit of 1 parasite in 10 000 erythrocytes (that is, 0.01%).

Accumulation Experiment. Synchronized PRBCs were obtained following two cycles of sorbitol-induced lysis of an asynchronous stock culture. Incubation for an additional 20−24 h provided a population of mature trophozoites that were added to the culture medium at 2% v/v (about/10% parasitemia).

An aliquot of a 10 mM solution of **1** was added to a culture flask containing 5 mL of PRBCs suspended in complete medium (10% parasitemia) such that the initial medium concentration of **1** was ~5 μM. Samples were removed from the flask at various intervals and centrifuged; the supernatant fluid was then removed and refrigerated before analysis. **1** was added to flasks containing both CQS D6- and CQR Dd2-infected RBCs and, as a control, to a flask containing uninfected RBCs. For the purpose of estimating the amount of **1** accumulated within the DV, NH_4Cl (10 mM) was added 10 min prior to sampling in order to basify the acidic subcellular compartments and cause the release of accumulated **1**. The samples were analyzed by reverse-phase HPLC, using a C18 column, eluting with an isocratic mixture of 75% acetonitrile/25% 5 mM phosphate buffer (pH 11). A parallel experiment was performed with CQ, also at ~5 μM, for comparative purposes. With these conditions **1** had a retention time of 14 min and CQ had 5 min. Each drug sample was monitored at 325 nm and was compared to a standard curve for quantification.

In Vitro Heme Binding and β-Hematin Inhibition. For heme−drug binding studies, a 1 mM stock solution of chloroquine or test compound was prepared in distilled water, methanol, or dimethyl sulfoxide (DMSO), depending on solubility, and sonicated to ensure complete dissolution. A 5 mM stock solution of heme was prepared by dissolving heme chloride in 0.1 mM NaOH by incubating at 37 °C for 30 min. The solution was stored at 4 °C for up to 1 month. At the beginning of each experiment, the stock heme solution was diluted to 5 μM in phosphate buffer (100 mM, pH 5.7) and allowed to equilibrate for 4 h. The 4 h equilibration allowed for the initial heme absorbance to stabilize prior to beginning the titration. Optical titrations with each compound were performed by successive addition of aliquots of its stock solution to the 5 μM heme solution. The pH was monitored throughout the procedure with only negligible (±0.05 pH units) changes. Equilibrium binding constants were determined by nonlinear least-squares analysis.[41]

Hemin chloride (16.3 mg) was dissolved in 1 mL of DMSO. The solution was passed through a 0.2 μm pore membrane filter to remove insoluble particles and kept at 4 °C for up to 1 month as a stock solution.[42] In order to determine heme concentration of the stock solution, a sample was diluted in 2.5% sodium dodecyl sulfate in 0.1 M NaOH and an absorbance reading taken at 400 nm. The heme concentration was calculated using Beer's law with a molar absorptivity $\varepsilon = 10^5$ mol L^{-1} cm^{-1}. The optimal heme and Tween-20 concentrations for promoting heme crystallization were calculated by the procedure described by Huy.[43] The RCQ compounds were screened for their inhibitory capacity, and IC_{50} values were determined. Assays were run in duplicate twice. Incubations were conducted in the dark to ensure that light did not interfere. A series of solutions were made consisting of 300 μL of varying concentrations of the compound under study in distilled water, 700 μL of 1 M acetate buffer, 300 μL of a 200 μM heme solution freshly buffered by 1 M sodium acetate (pH 4.8), and 200 μL of 0.0375 g/L Tween-20 solution. This provided a final 40 μM heme solution buffered by 0.67 M sodium acetate at pH 4.8 and 0.0005 g/L Tween20, with the test compound ranging in concentration from 0 to 1000 μM. The mixtures were incubated for 24 h at 37 °C,[35] then mixed and transferred to a cuvette for a 415/630 nm absorbance reading. IC_{50} values were calculated by $(D_{max} - D_{initial})/2$ where D_{max} represents the lowest concentration of compound under study to provide maximal absorbance readings indicating maximal free heme, and $D_{initial}$ represents the lowest concentration of drug to provide any increase in absorbance over a solution with no drug.

In Vivo Hemozoin Inhibition Experiment. *P. falciparum* strains D6 and Dd2 were synchronized to the ring stage (early trophozoites) with 5% sobitol solution.[24] After the synchronization of the parasites, the erythrocytes were suspended in culture medium at 1% hematocrit and aliquots of 1 mM stock solution of drug were added to the culture flasks. Drug treated cultures, along with the no-drug control culture, were incubated for 24 h at 37 °C under a gas mixture of 5% O_2, 5% CO_2, and 90% N_2 and then transferred to 15 mL centrifuge tubes. One 2 μL aliquot was used from each tube to obtain Giemsa-stained smear for determination of the parasitemia and morphology examination by microscopy.

Parasites were isolated by one freeze−thaw cycle at −20 °C and treated with a saponin-containing lysis buffer (Tris (20 mM, pH 7.5), EDTA (5 mM), saponin (0.008%, w/v), and Triton X-100 (0.08%, v/v)[40] at 37 °C for 30 min. The hemozoin was pelleted by centrifugation at 215,000 g for 30 min at 25 °C. The supernatant was removed, and the pellet consisting primarily of hemozoin was washed two times with acetone to remove residual proteins. Insoluble material was then washed three times with PBS (pH 7.4) buffer and collected by centrifugation at 215000g for 30 min at 25 °C. The pellet was dissolved with 0.2 N

sodium hydroxide for 2 h at 37 °C and periodic mixing of the sample. The absorbance at 400 nm was measured, and the amount of heme was calculated using an extinction coefficient of 91 000 cm^{-1} M^{-1}.[36−38] The amount of heme per parasitized erythrocyte was calculated on the basis of the number of erythrocytes in the culture and the percent parasitemia obtained after growing synchronized culture for 24 h. Cultures at 0 h processed with the identical method were used for determination of the baseline hemozoin production.

Acknowledgment. The authors thank the following for supporting this research: The Medical Research Foundation of Oregon (Grant 0530) and the National Institutes of Health (Grants AI067837 and AI072923) to D.H.P., as well as the Murdock Charitable Trust for a grant for the NMR instruments. The authors also thank Westin Morrill for his help in preparing this manuscript.

References

(1) *World Malaria Report 2009*; World Health Organization: Geneva, Switzerland, 2009.
(2) Jambou, R.; Legrand, E.; Niang, M.; Khim, N.; Lim, P.; Volney, B.; Ekala, M. T.; Bouchier, C.; Esterre, P.; Fandeur, T.; Mercereau-Puijalon, O. Resistance of *Plasmodium falciparum* field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. *Lancet* **2005**, *366*, 1960–1963.
(3) Andriantsoanirina, V.; Ratsimbasoa, A.; Bouchier, C.; Jahevitra, M.; Rabearimanana, S.; Radrianjafy, R.; Andrianaranjaka, V.; Randriantsoa, T.; Rason, M. A.; Tichit, M.; Rabarijaona, L. P.; Mercereau-Puijalon, O.; Durand, R.; Menard, D. *Plasmodium falciparum* drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility. *Antimicrob. Agents Chemother.* **2009**, *53*, 4588–4597.
(4) Wongsrichanalai, C.; Meshnick, S. R. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia−Thailand border. *Emerging Infect. Dis.* **2008**, *14*, 716–719.
(5) Dondorp, A. M.; Nosten, F.; Yi, P.; Das, D.; Phyo, A. P.; Tarning, J.; Lwin, K. M.; Ariey, F.; Hanpithakpong, W.; Lee, S. J.; Ringwald, P.; Silamut, K.; Imwong, M.; Chotivanich, K.; Lim, P.; Herdman, T.; An, S. S.; Yeung, S.; Singhasivanon, P.; Day, N. P.; Lindegardh, N.; Socheat, D.; White, N. J. Artemisinin resistance in *Plasmodium falciparum* malaria. *N. Engl. J. Med.* **2009**, *361*, 455–467.
(6) Giha, H. A. Artemisinin derivatives for treatment of uncomplicated *Plasmodium falciparum* malaria in Sudan: too early for too much hope. *Parasitol. Res.* **2010**, *106*, 549–552.
(7) Zhang, H.; Paguio, M.; Roepe, P. D. The antimalarial drug resistance protein *Plasmodium falciparum* chloroquine resistance transporter binds chloroquine. *Biochemistry* **2004**, *43*, 8290–8296.
(8) Martin, R. E.; Kirk, K. The malaria parasite's chloroquine resistance transporter is a member of the drug/metabolite transporter superfamily. *Mol. Biol. Evol.* **2004**, *21*, 1938–1949.
(9) Bray, P. G.; Martin, R. E.; Tilley, L.; Ward, S. A.; Kirk, K.; Fidock, D. A. Defining the role of PfCRT in *Plasmodium falciparum* chloroquine resistance. *Mol. Microbiol.* **2005**, *56*, 323–333.
(10) Fidock, D. A.; Nomura, T.; Talley, A. K.; Cooper, R. A.; Dzekunov, S. M.; Ferdig, M. T.; Ursos, L. M.; Sidhu, A. B.; Naude, B.; Deitsch, K. W.; Su, X. Z.; Wootton, J. C.; Roepe, P. D.; Wellems, T. E. Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. *Mol. Cell* **2000**, *6*, 861–871.
(11) Krogstad, D. J.; Gluzman, I. Y.; Kyle, D. E.; Oduola, A. M.; Martin, S. K.; Milhous, W. K.; Schlesinger, P. H. Efflux of chloroquine from *Plasmodium falciparum*: mechanism of chloroquine resistance. *Science* **1987**, *238*, 1283–1285.
(12) Martin, R. E.; Marchetti, R. V.; Cowan, A. I.; Howitt, S. M.; Broer, S.; Kirk, K. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. *Science* **2009**, *325*, 1680–1682.
(13) Martin, S. K.; Oduola, A. M.; Milhous, W. K. Reversal of chloroquine resistance in *Plasmodium falciparum* by verapamil. *Science* **1987**, *235*, 899–901.
(14) Bitonti, A. J.; Sjoerdsma, A.; McCann, P. P.; Kyle, D. E.; Oduola, A. M. J.; Rossan, R. N.; Milhous, W. K.; Davidson, D. E. Reversal of chloroquine resistance in malaria parasite *Plasmodium falciparum* by desipramine. *Science* **1988**, *242*, 1301–1303.
(15) Kelly, J. X.; Smilkstein, M. J.; Cooper, R. A.; Lane, K. D.; Johnson, R. A.; Janowsky, A.; Dodean, R. A.; Hinrichs, D. J.; Winter, R.; Riscoe, M. Design, synthesis, and evaluation of 10-*N*-substituted acridones as novel chemosensitizers in *Plasmodium falciparum*. *Antimicrob. Agents Chemother.* **2007**, *51*, 4133–4140.
(16) Bhattacharjee, A. K.; Kyle, D. E.; Vennerstrom, J. L.; Milhous, W. K. A 3D QSAR pharmacophore model and quantum chemical structure−activity analysis of chloroquine (CQ)-resistance reversal. *J. Chem. Inf. Model.* **2002**, *42*, 1212–1220.
(17) Burgess, S. J.; Selzer, A.; Kelly, J. X.; Smilkstein, M. J.; Riscoe, M. K.; Peyton, D. H. A chloroquine-like molecule designed to reverse resistance in *Plasmodium falciparum*. *J. Med. Chem.* **2006**, *49*, 5623–5625.
(18) Andrews, S.; Burgess, S. J.; Skaalrud, D.; Kelly, J. X.; Peyton, D. H. Reversal agent and linker variants of reversed chloroquines: activities against *Plasmodium falciparum*. *J. Med. Chem.* **2010**, *53*, 916–919.
(19) Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. *J. Org. Chem.* **1996**, *61*, 3849–3862.
(20) De, D.; Krogstad, F. M.; Cogswell, F. B.; Krogstad, D. J. Aminoquinolines that circumvent resistance in *Plasmodium falciparum* in vitro. *Am. J. Trop. Med. Hyg.* **1996**, *55*, 579–583.
(21) Hofheinz, W.; Jaquet, C.; Jolidon, S. Aminochinoline Derivates Useful in the Treatment of Malaria. EP0656353, 1995.
(22) Ridley, R. G.; Hofheinz, W.; Matile, H.; Jaquet, C.; Dorn, A.; Masciadri, R.; Jolidon, S.; Richter, W. F.; Guenzi, A.; Girometta, M. A.; Urwyler, H.; Huber, W.; Thaithong, S.; Peters, W. 4-Aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant *Plasmodium falciparum*. *Antimicrob. Agents Chemother.* **1996**, *40*, 1846–1854.
(23) Martin, Y. C. A bioavailability score. *J. Med. Chem.* **2005**, *48*, 3164–3170.
(24) Kelly, J. X.; Winter, R. W.; Cornea, A.; Peyton, D. H.; Hinrichs, D. J.; Riscoe, M. The kinetics of uptake and accumulation of 3,6-bis-ω-diethylamino-amyloxyxanthone by the human malaria parasite *Plasmodium falciparum*. *Mol. Biochem. Parasitol.* **2002**, *123*, 47–54.
(25) Sullivan, D. J., Jr.; Gluzman, I. Y.; Russell, D. G.; Goldberg, D. E. On the molecular mechanism of chloroquine's antimalarial action. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 11865–11870.
(26) Jacobs, G. H.; Aikawa, M.; Milhous, W. K.; Rabbege, J. R. An ultrastructural study of the effects of mefloquine on malaria parasites. *Am. J. Trop. Med. Hyg.* **1987**, *36*, 9–14.
(27) Jacobs, G. H.; Oduola, A. M.; Kyle, D. E.; Milhous, W. K.; Martin, S. K.; Aikawa, M. Ultrastructural study of the effects of chloroquine and verapamil on *Plasmodium falciparum*. *Am. J. Trop. Med. Hyg.* **1988**, *39*, 15–20.
(28) Cabrera, M.; Paguio, M. F.; Xie, C.; Roepe, P. D. Reduced digestive vacuolar accumulation of chloroquine is not linked to resistance to chloroquine toxicity. *Biochemistry* **2009**, *48*, 11152–11154.
(29) Gligorijevic, B.; Purdy, K.; Elliott, D. A.; Cooper, R. A.; Roepe, P. D. Stage independent chloroquine resistance and chloroquine toxicity revealed via spinning disk confocal microscopy. *Mol. Biochem. Parasitol.* **2008**, *159*, 7–23.
(30) Mzayek, F.; Deng, H.; Mather, F. J.; Wasilevich, E. C.; Liu, H.; Hadi, C. M.; Chansolme, D. H.; Murphy, H. A.; Melek, B. H.; Tenaglia, A. N.; Mushatt, D. M.; Dreisbach, A. W.; Lertora, J. J.; Krogstad, D. J. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. *PLoS Clin. Trials* **2007**, *2*, e6.
(31) Stepniewska, K.; White, N. J. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. *Antimicrob. Agents Chemother.* **2008**, *52*, 1589–1596.
(32) Chou, A. C.; Chevli, R.; Fitch, C. D. Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites. *Biochemistry* **1980**, *19*, 1543–1549.
(33) Dorn, A.; Vippagunta, S. R.; Matile, H.; Jaquet, C.; Vennerstrom, J. L.; Ridley, R. G. An assessment of drug−haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. *Biochem. Pharmacol.* **1998**, *55*, 727–736.
(34) Egan, T. J. Interactions of quinoline antimalarials with hematin in solution. *J. Inorg. Biochem.* **2006**, *100*, 916–926.
(35) Egan, T. J.; Ncokazi, K. K. Quinoline antimalarials decrease the rate of beta-hematin formation. *J. Inorg. Biochem.* **2005**, *99*, 1532–1539.
(36) Bonilla, J. A.; Moura, P. A.; Bonilla, T. D.; Yowell, C. A.; Fidock, D. A.; Dame, J. B. Effects on growth, hemoglobin metabolism and

paralogous gene expression resulting from disruption of genes encoding the digestive vacuole plasmepsins of *Plasmodium falciparum*. *Int. J. Parasitol.* **2007**, *37*, 317–327.
(37) Pandey, A. V.; Singh, N.; Tekwani, B. L.; Puri, S. K.; Chauhan, V. S. Assay of β-hematin formation by malaria parasite. *J. Pharm. Biomed. Anal.* **1999**, *20*, 203–207.
(38) Pandey, A. V.; Joshi, S. K.; Tekwani, B. L.; Chauhan, V. S. A colorimetric assay for heme in biological samples using 96-well plates. *Anal. Biochem.* **1999**, *268*, 159–161.
(39) Leonardi, A.; Barlocco, D.; Montesano, F.; Cignarella, G.; Motta, G.; Testa, R.; Poggesi, E.; Seeber, M.; DeBenedetti, P. G.; Fanelli, F. Synthesis, screening, and molecular modeling of new potent and selective antagonists at the α_{1d} adrenergic receptor. *J. Med. Chem.* **2004**, *47*, 1900–1918.
(40) Smilkstein, M.; Sriwilaijaroen, N.; Kelly, J. X.; Wilairat, P.; Riscoe, M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. *Antimicrob. Agents Chemother.* **2004**, *48*, 1803–1806.
(41) Connors, K. A. *Binding Constants: The Measurement of Molecular Complex Stability*; Wiley: New York, 1987.
(42) Trang, D. T.; Huy, N. T.; Uyen, D. T.; Sasai, M.; Shiono, T.; Harada, S.; Kamei, K. Inhibition assay of beta-hematin formation initiated by lecithin for screening new antimalarial drugs. *Anal. Biochem.* **2006**, *349*, 292–296.
(43) Huy, N. T.; Kamei, K.; Yamamoto, T.; Kondo, Y.; Kanaori, K.; Takano, R.; Tajima, K.; Hara, S. Clotrimazole binds to heme and enhances heme-dependent hemolysis: proposed antimalarial mechanism of clotrimazole. *J. Biol. Chem.* **2002**, *277*, 4152–4158.